Premium
Antifungal susceptibility and genotypes of Candida albicans strains from patients with vulvovaginal candidiasis
Author(s) -
Liu X. P.,
Fan S. R.,
Bai F. Y.,
Li J.,
Liao Q. P.
Publication year - 2009
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2008.01539.x
Subject(s) - candida albicans , genotype , corpus albicans , itraconazole , microbiology and biotechnology , fluconazole , ketoconazole , biology , amphotericin b , antifungal , gene , genetics
Summary Studies of the genetic diversity of Candida albicans strains and the correlation between the antifungal susceptibility and gene diversity of C. albicans were carried out and the results were found to be inconsistent. To investigate antifungal susceptibility and genotypes of C. albicans strains from patients with vulvovaginal candidiasis (VVC), the genotypes of C. albicans in patients with VVC were studied using a recently developed polymerase chain reaction‐single strand conformation polymorphism (PCR‐SSCP) of CAI microsatellite method and antifungal susceptibility was tested using E‐test methods. Twenty‐six genotypes were identified from 89 strains of C. albicans isolated from patients with VVC. Candida albicans isolates were susceptible to amphotericin B, flucytosine, ketoconazole and fluconazole. The dominant genotypes (A, B, C, D) account for 69.7% (62/89) of C. albicans . The resistant rate of C. albicans genotype B to itraconazole (ITR) and that of C. albicans non‐genotype B strains were 66.7% (14/21) and 4.4% (3/68) respectively at P < 0.05. We concluded that C. albicans genotype B from patients with VVC was more resistant to ITR.